**Description**

**A FORMULATION INTENDED TO DISPLAY AN ANTI-CARCINOGENIC EFFECT BY MEK SUPPRESSION METHOD**

**Field of Invention**

The present invention herewith discloses a formulation developed to display an anti-carcinogenic affect by mek suppression method.

**Background of the Related Technology**

At present it is known that an anti-carcinogenic substance is any agent that prevents the development of cancer or prevents the growth of tumor. In state of art technology, invention no “WO 1997/048409", with title “Using Naaladase Inhibitors In Treatment Of Cancer” and under classification number “A61K 38/05" discloses dipeptidase inhibitors and more specifically new methods where the phosphanate derivatives, hydroxyphosphonyl derivatives and phophoramidate derivatives are used with the compounds related to this invention, for inhibiting the enzyme activity of N-acetylated α-linked acidic dipeptidase (NAALADase) and for treatment to prevent the progress of diseases and specifically the growth of prostate cancer cells.

Again invention no “WO 1997/005873", with title “Using Fluconazole to Prevent Progress of Cancer Diseases” and under classification number “A61K 31/41" discloses a pharmaceutical composition for curing of cancers or tumors in mammals, where this compositions contains 2-(2,4-difluorophenyl)-1, 3-bis(1H-1,2,4-triazole-1-yl) propane-2-ol and its derivatives. A chemotherapeutic agent can be used with 2-(2,4-difluorophenyl)-1, 3-bis(1H-1,2,4-triazole-1-yl) propane-2-ol and its derivatives as enhancers. At the same time the 2-(2,4-difluorophenyl)-1, 3-bis(1H-1,2,4-triazole-1-yl) propane-2-ol and its derivatives, may be used for curing viral infections together with another anti-viral agent, alone or with an enhancer.

Again invention no “EP1373260B1", with title “Dibenzo[c]chromane-6-one derivatives as Anti-Carcinogenic Agents” and under classification number “C07D 407/04" discloses molecules that display anti-proliferative action against endothelial cells and epithelial cancer cell lines, as well as the methods for synthesizing such molecules. It is aimed to use these molecules in therapeutic preparates, intended for treatment of cancer, either by anti-angiogenesis or other anti-carcinogenic mechanisms. The referred compound is 6H-dibenzo[b,d]pyrane-6-one derivatives and it is demonstrated that these compounds are anti-proliferative against human endothelial cells.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended to display an anti-carcinogenic effect by mek suppression method

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the invention is to suppress pge-2 expression.
* One other objective of the invention is to suppress cox-2 expression.
* One other objective of the invention is to suppress MEK expression.

The present invention which is aimed to achieve the above-mentioned advantages, discloses a formulation intended to display an anti-carcinogenic effect by mek suppression method and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention herewith discloses a formulation developed to display an anti-carcinogenic affect by mek suppression method. Referred formulation suppresses pge-2 expression, suppresses cox-2 expression, suppresses MEK expression.

Cox-2 is an enzyme responsible for pain. Cyclooxygenase (cox) enzymes are enzymes responsible from formation of prostaglandin and eicosanoids from intracellular arachidonic acid. These enzymes have important functions in terms of hemostatic equilibrium. On the other hand, pge-2 is a prostaglandin derivative compound, PGE2, which formed by the action of PGE synthase enzyme over PGH2 in the body, and having an effect of dilating the blood vessels, preventing clustering of thrombocytes, relaxing smooth muscles of respiratory tract and also preventing dissolution of the yellow body in cattle, sheep and swine. Based on its smooth muscle relaxation characteristic, it is used as cervix dilators in cases the cervix uterus is not dilated sufficiently during childbirth.

Pge-2 is an important prostaglandin, the prostaglandin E2, is secreted by the medulla of the kidney, gastro-instestinal mucous layer and other tissues. It causes contraction and relaxation in smooth muscles. Based on its smooth muscle relaxation characteristic, it is used as cervix dilators in cases the cervix uterus is not dilated sufficiently during childbirth.

The formulation of the invention presented herewith contains; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside.

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 1-99% of 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one,
* 99-1% of (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time discloses using the above-referred formulation to display anti-carcinogenic affect by mek suppression method and also manufacturing it for such purpose.

**CLAIMS**

1. A formulation intended to display an anti-carcinogenic effect by mek suppression method, which consists of combining the components selected from the group; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside, in a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing 1-99% of 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one by weight.
3. The formulation of Claim 1 which is characterized by containing  99-1% of (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, (3β,5β)-19,20-trimethoxydamar-24-ene-3-coumaroyl 2-*O*-β-D-hexapyranosyl-β-D-diethylpyranoside from any one as given in Claims 2-3 in manufacturing the formulation intended to display anti-carcinogenic affect by mek suppression method.

**SUMMARY**

**A FORMULATION INTENDED TO HAVE AN ANTI-CARCINOGENIC EFFECT BY MEK SUPPRESSION METHOD**

The present invention herewith discloses a formulation developed to display an anti-carcinogenic affect by mek suppression method. Referred formulation suppresses pge-2 expression, suppresses cox-2 expression, suppresses MEK expression.

There are no illustrations.